Financhill
Buy
71

ABBV Quote, Financials, Valuation and Earnings

Last price:
$211.73
Seasonality move :
3.23%
Day range:
$208.29 - $212.82
52-week range:
$153.58 - $218.66
Dividend yield:
2.97%
P/E ratio:
88.24x
P/S ratio:
6.67x
P/B ratio:
112.44x
Volume:
4.5M
Avg. volume:
6.2M
1-year change:
16.87%
Market cap:
$373.8B
Revenue:
$56.3B
EPS (TTM):
$2.40

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ABBV
AbbVie
$14.7B $3.09 5.05% 227.63% $211.73
AMGN
Amgen
$8.9B $5.34 8.14% 257.4% $315.95
GILD
Gilead Sciences
$6.9B $1.93 1.18% 49.16% $111.26
JNJ
Johnson & Johnson
$22.4B $2.72 1.23% 96.75% $169.07
LLY
Eli Lilly and
$14.2B $5.47 45.75% 89.16% $1,006.63
VRTX
Vertex Pharmaceuticals
$2.9B $4.34 5.83% 2.33% $496.78
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ABBV
AbbVie
$211.77 $211.73 $373.8B 88.24x $1.64 2.97% 6.67x
AMGN
Amgen
$313.71 $315.95 $168.5B 41.55x $2.38 2.91% 5.07x
GILD
Gilead Sciences
$111.44 $111.26 $138.8B 301.19x $0.79 2.78% 4.87x
JNJ
Johnson & Johnson
$162.81 $169.07 $392.3B 28.12x $1.24 3.05% 4.45x
LLY
Eli Lilly and
$813.48 $1,006.63 $730.6B 69.47x $1.50 0.66% 16.33x
VRTX
Vertex Pharmaceuticals
$504.77 $496.78 $129.6B 26.10x $0.00 0% 11.88x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ABBV
AbbVie
95.28% -0.007 22.34% 0.43x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
GILD
Gilead Sciences
58.02% 0.435 23.22% 1.33x
JNJ
Johnson & Johnson
33.88% 0.530 10.52% 0.86x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
VRTX
Vertex Pharmaceuticals
-- 1.364 -- 2.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ABBV
AbbVie
$10.7B $84M 5.68% 61.64% -10.38% $6.8B
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
GILD
Gilead Sciences
$6B $2.4B 1.09% 2.5% 31.92% $2.8B
JNJ
Johnson & Johnson
$15.4B $3.8B 13.3% 19.98% 17.87% $4.8B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $492M

AbbVie vs. Competitors

  • Which has Higher Returns ABBV or AMGN?

    Amgen has a net margin of -0.15% compared to AbbVie's net margin of 6.9%. AbbVie's return on equity of 61.64% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABBV
    AbbVie
    70.89% -$0.02 $70.5B
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About ABBV or AMGN?

    AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.02%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 0.71%. Given that Amgen has higher upside potential than AbbVie, analysts believe Amgen is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABBV
    AbbVie
    11 10 0
    AMGN
    Amgen
    9 14 2
  • Is ABBV or AMGN More Risky?

    AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock ABBV or AMGN?

    AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Amgen offers a yield of 2.91% to investors and pays a quarterly dividend of $2.38 per share. AbbVie pays 257.71% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ABBV or AMGN?

    AbbVie quarterly revenues are $15.1B, which are larger than Amgen quarterly revenues of $9.1B. AbbVie's net income of -$22M is lower than Amgen's net income of $627M. Notably, AbbVie's price-to-earnings ratio is 88.24x while Amgen's PE ratio is 41.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 5.07x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABBV
    AbbVie
    6.67x 88.24x $15.1B -$22M
    AMGN
    Amgen
    5.07x 41.55x $9.1B $627M
  • Which has Higher Returns ABBV or GILD?

    Gilead Sciences has a net margin of -0.15% compared to AbbVie's net margin of 23.56%. AbbVie's return on equity of 61.64% beat Gilead Sciences's return on equity of 2.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABBV
    AbbVie
    70.89% -$0.02 $70.5B
    GILD
    Gilead Sciences
    79.11% $1.42 $46B
  • What do Analysts Say About ABBV or GILD?

    AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.02%. On the other hand Gilead Sciences has an analysts' consensus of $111.26 which suggests that it could fall by -0.16%. Given that Gilead Sciences has more downside risk than AbbVie, analysts believe AbbVie is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABBV
    AbbVie
    11 10 0
    GILD
    Gilead Sciences
    15 11 0
  • Is ABBV or GILD More Risky?

    AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

  • Which is a Better Dividend Stock ABBV or GILD?

    AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Gilead Sciences offers a yield of 2.78% to investors and pays a quarterly dividend of $0.79 per share. AbbVie pays 257.71% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ABBV or GILD?

    AbbVie quarterly revenues are $15.1B, which are larger than Gilead Sciences quarterly revenues of $7.6B. AbbVie's net income of -$22M is lower than Gilead Sciences's net income of $1.8B. Notably, AbbVie's price-to-earnings ratio is 88.24x while Gilead Sciences's PE ratio is 301.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 4.87x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABBV
    AbbVie
    6.67x 88.24x $15.1B -$22M
    GILD
    Gilead Sciences
    4.87x 301.19x $7.6B $1.8B
  • Which has Higher Returns ABBV or JNJ?

    Johnson & Johnson has a net margin of -0.15% compared to AbbVie's net margin of 15.24%. AbbVie's return on equity of 61.64% beat Johnson & Johnson's return on equity of 19.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABBV
    AbbVie
    70.89% -$0.02 $70.5B
    JNJ
    Johnson & Johnson
    68.35% $1.41 $108.1B
  • What do Analysts Say About ABBV or JNJ?

    AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.02%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that Johnson & Johnson has higher upside potential than AbbVie, analysts believe Johnson & Johnson is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABBV
    AbbVie
    11 10 0
    JNJ
    Johnson & Johnson
    7 13 0
  • Is ABBV or JNJ More Risky?

    AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

  • Which is a Better Dividend Stock ABBV or JNJ?

    AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. AbbVie pays 257.71% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

  • Which has Better Financial Ratios ABBV or JNJ?

    AbbVie quarterly revenues are $15.1B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. AbbVie's net income of -$22M is lower than Johnson & Johnson's net income of $3.4B. Notably, AbbVie's price-to-earnings ratio is 88.24x while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABBV
    AbbVie
    6.67x 88.24x $15.1B -$22M
    JNJ
    Johnson & Johnson
    4.45x 28.12x $22.5B $3.4B
  • Which has Higher Returns ABBV or LLY?

    Eli Lilly and has a net margin of -0.15% compared to AbbVie's net margin of 32.59%. AbbVie's return on equity of 61.64% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABBV
    AbbVie
    70.89% -$0.02 $70.5B
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About ABBV or LLY?

    AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.02%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than AbbVie, analysts believe Eli Lilly and is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABBV
    AbbVie
    11 10 0
    LLY
    Eli Lilly and
    16 4 0
  • Is ABBV or LLY More Risky?

    AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock ABBV or LLY?

    AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. AbbVie pays 257.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

  • Which has Better Financial Ratios ABBV or LLY?

    AbbVie quarterly revenues are $15.1B, which are larger than Eli Lilly and quarterly revenues of $13.5B. AbbVie's net income of -$22M is lower than Eli Lilly and's net income of $4.4B. Notably, AbbVie's price-to-earnings ratio is 88.24x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABBV
    AbbVie
    6.67x 88.24x $15.1B -$22M
    LLY
    Eli Lilly and
    16.33x 69.47x $13.5B $4.4B
  • Which has Higher Returns ABBV or VRTX?

    Vertex Pharmaceuticals has a net margin of -0.15% compared to AbbVie's net margin of 31.35%. AbbVie's return on equity of 61.64% beat Vertex Pharmaceuticals's return on equity of -3.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABBV
    AbbVie
    70.89% -$0.02 $70.5B
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
  • What do Analysts Say About ABBV or VRTX?

    AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.02%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -1.58%. Given that Vertex Pharmaceuticals has more downside risk than AbbVie, analysts believe AbbVie is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABBV
    AbbVie
    11 10 0
    VRTX
    Vertex Pharmaceuticals
    16 12 1
  • Is ABBV or VRTX More Risky?

    AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

  • Which is a Better Dividend Stock ABBV or VRTX?

    AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AbbVie pays 257.71% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ABBV or VRTX?

    AbbVie quarterly revenues are $15.1B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.9B. AbbVie's net income of -$22M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, AbbVie's price-to-earnings ratio is 88.24x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 11.88x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABBV
    AbbVie
    6.67x 88.24x $15.1B -$22M
    VRTX
    Vertex Pharmaceuticals
    11.88x 26.10x $2.9B $913M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock